SeekingAlpha · Feb 3, 2026
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026
Altimmune, Inc. closed a $75 million direct offering to fund Phase 3 pemvidutide trials for MASH. Learn more about ALT stock here.
AL
NASDAQ · ALT
Altimmune, Inc.
Healthcare · Biotechnology
$3.35
Down-$0.06 (-1.79%)
Updated Sep 10, 2026, 9:58 PM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 380.39M
- P/E ratio
- -4.59
- Dividend yield
- 0.00%
- 52-week range
- $2.56 – $4.04
- Volume
- 3.08M
- Avg. volume
- 4.9M
Price performance
ALT price history
1M range · 20 trading sessions · Daily adjusted prices
ALT closed at $3.35 after 20 trading sessions, up 14.33% for the selected period.
- Last close
- $3.35
- Period change
- +14.33%
- Period low
- $2.88
- Period high
- $3.42
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $3.35 | $3.425 | $3.291 | $3.35 | 3.08M |
| Sep 8, 2026 | $3.46 | $3.5499 | $3.34 | $3.36 | 3.59M |
| Sep 4, 2026 | $3.28 | $3.43 | $3.25 | $3.42 | 4.87M |
| Sep 3, 2026 | $3.30 | $3.32 | $3.19 | $3.23 | 2.55M |
| Sep 2, 2026 | $3.10 | $3.34 | $3.10 | $3.28 | 7.47M |
| Sep 1, 2026 | $3.07 | $3.095 | $3.02 | $3.09 | 2.36M |
| Aug 31, 2026 | $3.08 | $3.135 | $3.06 | $3.11 | 2.22M |
| Aug 28, 2026 | $3.21 | $3.23 | $3.06 | $3.11 | 3.19M |
| Aug 27, 2026 | $3.19 | $3.25 | $3.1301 | $3.24 | 2.28M |
| Aug 26, 2026 | $3.20 | $3.20 | $3.09 | $3.15 | 4.05M |
| Aug 25, 2026 | $3.14 | $3.225 | $3.11 | $3.20 | 3.82M |
| Aug 24, 2026 | $3.13 | $3.13 | $3.025 | $3.11 | 2.72M |
| Aug 21, 2026 | $2.98 | $3.24 | $2.95 | $3.11 | 6.16M |
| Aug 20, 2026 | $3.07 | $3.08 | $2.92 | $2.95 | 4.68M |
| Aug 19, 2026 | $3.04 | $3.20 | $3.005 | $3.12 | 10.82M |
| Aug 18, 2026 | $2.99 | $3.03 | $2.96 | $2.97 | 2.47M |
| Aug 17, 2026 | $2.94 | $3.02 | $2.90 | $3.00 | 4.06M |
| Aug 14, 2026 | $2.95 | $2.97 | $2.86 | $2.94 | 3.07M |
| Aug 13, 2026 | $2.95 | $2.96 | $2.84 | $2.88 | 4.11M |
| Aug 12, 2026 | $3.05 | $3.20 | $2.92 | $2.93 | 6.05M |
Latest ALT news
The latest Smart Investors Daily articles mentioning ALT.
Stock researchCompany · Overview
ALT research
Overview
Company profile and research snapshot.
Company profile
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $23.60
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 22, 2026 | Leerink Partners | Outperform | — |
| May 18, 2026 | HC Wainwright & Co. | Buy | — |
| May 14, 2026 | Citizens | Market Outperform | — |
| Mar 16, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 6, 2026 | B. Riley Securities | Buy | — |
News briefing
No generated briefing is available yet.
SeekingAlpha · Jan 28, 2026
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet
Yahoo · Jan 6, 2026
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH
Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.
Yahoo · Jan 5, 2026
Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDAGAITHERSBURG, Md., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, today announced the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for pemvidutide, a balanced 1:1 glucagon/GLP-1 dual receptor agoni
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
